175 related articles for article (PubMed ID: 8556244)
1. [Seroprevalence of anti-hepatitis A antibodies in Czech soldiers serving in U.N. forces--suggestions for a hepatitis A vaccination schedule].
Beran J; Douda P; Prymula R; Splino M; Gál P; Rychlý R
Epidemiol Mikrobiol Imunol; 1995 Dec; 44(4):165-8. PubMed ID: 8556244
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis A vaccination by Havrix in the Czech U.N. Troops according to data of seroprevalence in 1991-1995.
Beran J; Douda P; Prymula R; Gál P; Rychlý R; Splino M
Cent Eur J Public Health; 1996 May; 4(2):87-90. PubMed ID: 8996717
[TBL] [Abstract][Full Text] [Related]
3. The seroprevalence of the "total" anti-HAV antibody in the Czech UNPRO Forces (1991-1995).
Beran J; Douda P; Gál P; Rychlý R; Prymula R; Splino M
Acta Medica (Hradec Kralove); 1996; 39(1):35-9. PubMed ID: 9106389
[TBL] [Abstract][Full Text] [Related]
4. [Seroprevalence of antibodies against hepatitis A virus and hepatitis B virus in nonvaccinated adult population over 40 years of age].
Chlíbek R; Cecetková B; Smetana J; Prymula R; Kohl I
Epidemiol Mikrobiol Imunol; 2006 Aug; 55(3):99-104. PubMed ID: 16970073
[TBL] [Abstract][Full Text] [Related]
5. [Seroepidemiology of hepatitis A virus infection in medical and nursing students. The role of vaccination].
Buti M; Campins M; Jardí R; Navas E; Cotrina M; Llobet E; Vaqué J; Esteban R
Gastroenterol Hepatol; 1996 Apr; 19(4):199-202. PubMed ID: 8665357
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
[TBL] [Abstract][Full Text] [Related]
7. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.
Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E
J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755
[TBL] [Abstract][Full Text] [Related]
8. [Vaccination against hepatitis A].
Giusti G; Russo M
Recenti Prog Med; 1992 Jun; 83(6):313-20. PubMed ID: 1323136
[TBL] [Abstract][Full Text] [Related]
9. Age related seroprevalence of antibodies to hepatitis A virus in Hyderabad, India.
Joshi N; Yr NK; Kumar A
Trop Gastroenterol; 2000; 21(2):63-5. PubMed ID: 10881625
[TBL] [Abstract][Full Text] [Related]
10. [Active immunization against hepatitis A. Comparison of various immunization schedules].
Müller R; Bock HL; Clemens R; Jilg W
Dtsch Med Wochenschr; 1993 Aug; 118(31):1101-4. PubMed ID: 8393760
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine.
Vidor E; Xueref C; Blondeau C; Bajard A; Francon A; Goudeau A; Peyron F; Brasseur P; Zuckerman A
Biologicals; 1996 Sep; 24(3):235-42. PubMed ID: 8978923
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
[TBL] [Abstract][Full Text] [Related]
13. The 2001 serological survey in the Czech Republic--viral hepatitis.
Nemecek V; Cástková J; Fritz P; Linhartová A; Svandová E; Srámová H; Kríz B
Cent Eur J Public Health; 2003 Dec; 11 Suppl():S54-61. PubMed ID: 15080261
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
[TBL] [Abstract][Full Text] [Related]
15. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of anti-hepatitis B and anti-hepatitis A antibodies among school aged children in Western Saudi Arabia.
Jaber SM
Saudi Med J; 2006 Oct; 27(10):1515-22. PubMed ID: 17013474
[TBL] [Abstract][Full Text] [Related]
17. Cost-effective analysis of hepatitis A prevention in Ireland.
Rajan E; Shattock AG; Fielding JF
Am J Gastroenterol; 2000 Jan; 95(1):223-6. PubMed ID: 10638588
[TBL] [Abstract][Full Text] [Related]
18. Cell mediated and antibody immune response to inactivated hepatitis A vaccine.
Schmidtke P; Habermehl P; Knuf M; Meyer CU; Sänger R; Zepp F
Vaccine; 2005 Oct; 23(44):5127-32. PubMed ID: 16054733
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix.
Connor BA; Phair J; Sack D; McEniry D; Hornick R; Banerjee D; Jensen E; Kuter B
Clin Infect Dis; 2001 Feb; 32(3):396-401. PubMed ID: 11170947
[TBL] [Abstract][Full Text] [Related]
20. [Protection of adolescents against hepatitis A].
Puntarić D; Baklaić Z; Ljubicíc M; Vodopija I
Lijec Vjesn; 1996 Oct; 118(10):241-3. PubMed ID: 9132523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
